CVRX
CVRx, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$3.05
+1.33%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 61.2M | 56.7M | 51.3M | 39.3M | 22.5M |
| Cost of Revenue | 8.2M | 8.3M | 8.3M | 6.3M | 5.0M |
| Gross Profit | 53.0M | 48.3M | 43.0M | 33.0M | 17.5M |
| Operating Expenses | |||||
| R&D Expense | 12.4M | 11.1M | 11.1M | 11.6M | 10.0M |
| SG&A Expense | 89.3M | 88.5M | 91.3M | 64.5M | 50.0M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 101.6M | 99.6M | 102.4M | 76.1M | 60.0M |
| Cost and Expenses | 109.8M | 107.9M | 110.8M | 82.4M | 65.0M |
| Operating Income (EBIT) | (48.6M) | (51.3M) | (59.5M) | (43.1M) | (42.5M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 6.0M | 5.8M | 4.4M | 1.8M | 165.0K |
| Net Interest Income | (6.0M) | (5.8M) | (4.4M) | (1.8M) | (165.0K) |
| Other Non-Op Income/Expense | (3.3M) | (2.1M) | (420.0K) | 2.1M | 1.2M |
| Non-Operating Income (excl Interest) | (2.7M) | (3.8M) | (4.0M) | (3.9M) | (1.4M) |
| EBT (Pre-Tax Income) | (52.0M) | (53.3M) | (59.9M) | (41.1M) | (41.3M) |
| Income Tax Expense | (8.0K) | (18.0K) | 55.0K | 147.0K | 109.0K |
| Bottom Line | |||||
| Net Income | (52.0M) | (53.3M) | (60.0M) | (41.2M) | (41.4M) |
| Earnings from Cont. Ops | (52.0M) | (53.3M) | (60.0M) | (41.2M) | (41.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (52.0M) | (53.3M) | (60.0M) | (41.2M) | (41.4M) |
| Per Share | |||||
| Basic EPS | ($1.98) | ($2.04) | ($2.65) | ($1.99) | ($2.02) |
| Diluted EPS | ($1.98) | ($2.04) | ($2.65) | ($1.99) | ($2.02) |
| Revenue Per Share | $2.31 | $2.17 | $2.27 | $1.90 | $1.10 |
| Shares | |||||
| Basic Shares Outstanding | 26.5M | 26.1M | 22.6M | 20.7M | 20.5M |
| Diluted Shares Outstanding | 26.5M | 26.1M | 22.6M | 20.8M | 20.5M |
| Profitability Metrics | |||||
| EBITDA | (45.0M) | (46.7M) | (54.9M) | (38.7M) | (40.7M) |
| D&A | 998.0K | 756.0K | 619.0K | 522.0K | 412.0K |
| EBIT | (45.9M) | (47.5M) | (55.5M) | (39.3M) | (41.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026